Free Trial

Zomedica (ZOM) News Today

Zomedica logo
$0.13 +0.01 (+4.42%)
(As of 12/20/2024 05:45 PM ET)
Zomedica Corp. stock logo
Zomedica (NYSEAMERICAN:ZOM) Trading Down 2.8% - Here's Why
Zomedica (NYSEAMERICAN:ZOM) Trading Down 2.8% - Here's What Happened
Zomedica Corp. stock logo
Noble Financial Comments on Zomedica FY2024 Earnings
Zomedica Corp. (NYSEAMERICAN:ZOM - Free Report) - Analysts at Noble Financial issued their FY2024 earnings estimates for shares of Zomedica in a research report issued on Monday, November 11th. Noble Financial analyst R. Leboyer anticipates that the company will post earnings per share of ($0.05)
Zomedica Corp. stock logo
Zomedica Corp. (NYSEAMERICAN:ZOM) Director Johnny D. Powers Acquires 100,000 Shares
Zomedica Corp. (NYSEAMERICAN:ZOM - Get Free Report) Director Johnny D. Powers acquired 100,000 shares of Zomedica stock in a transaction dated Monday, November 11th. The stock was purchased at an average price of $0.12 per share, with a total value of $12,000.00. Following the completion of the purchase, the director now owns 2,425,000 shares of the company's stock, valued at approximately $291,000. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Zomedica Corp. stock logo
Zomedica (NYSEAMERICAN:ZOM) Stock Rating Upgraded by Noble Financial
Noble Financial upgraded Zomedica to a "strong-buy" rating in a research report on Monday.
Zomedica Corp Posts Increased Revenue Amid Loss
Zomedica’s Revenue Up 10% Amid Global Expansion
Zomedica Corp. (ZOM) Q3 2024 Earnings Call Transcript
Zomedica Corp. ZOM (U.S.: NYSE American)
Zomedica Corp. stock logo
Zomedica Corp. (NYSEAMERICAN:ZOM) CEO Larry C. Heaton II Buys 100,000 Shares
Zomedica Corp. (NYSEAMERICAN:ZOM - Get Free Report) CEO Larry C. Heaton II purchased 100,000 shares of Zomedica stock in a transaction on Thursday, September 5th. The stock was bought at an average cost of $0.12 per share, for a total transaction of $12,000.00. Following the transaction, the chief executive officer now directly owns 400,000 shares in the company, valued at $48,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Zomedica Corp. stock logo
Zomedica Corp. (NYSEAMERICAN:ZOM) Director Buys $13,000.00 in Stock
Zomedica Corp. (NYSEAMERICAN:ZOM - Get Free Report) Director Johnny D. Powers bought 100,000 shares of the stock in a transaction dated Wednesday, August 28th. The shares were acquired at an average price of $0.13 per share, with a total value of $13,000.00. Following the completion of the purchase, the director now directly owns 2,325,000 shares of the company's stock, valued at $302,250. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
WORK Medical Technology Group LTD Ordinary Shares (WOK)
Zomedica Corp. stock logo
Zomedica (NYSEAMERICAN:ZOM) Stock Price Down 5.5%
Zomedica (NYSEAMERICAN:ZOM) Trading Down 5.5%
ZOM Stock Earnings: Zomedica Misses Revenue for Q2 2024
Zomedica Corp. stock logo
Russell Kevin Klass Buys 299,993 Shares of Zomedica Corp. (NYSEAMERICAN:ZOM) Stock
Zomedica Corp. (NYSEAMERICAN:ZOM - Get Free Report) VP Russell Kevin Klass purchased 299,993 shares of the company's stock in a transaction dated Wednesday, June 12th. The stock was acquired at an average price of $0.16 per share, with a total value of $47,998.88. Following the completion of the transaction, the vice president now owns 2,000,050 shares of the company's stock, valued at approximately $320,008. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Zomedica Corp. stock logo
Insider Buying: Zomedica Corp. (NYSEAMERICAN:ZOM) COO Buys 150,000 Shares of Stock
Zomedica Corp. (NYSEAMERICAN:ZOM - Get Free Report) COO Anthony K. Blair purchased 150,000 shares of the stock in a transaction dated Monday, May 13th. The shares were bought at an average price of $0.14 per share, with a total value of $21,000.00. Following the completion of the acquisition, the chief operating officer now directly owns 150,000 shares of the company's stock, valued at approximately $21,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Zomedica earnings: here's what Wall Street expects
Q4 2023 Zomedica Corp Earnings Call
Zomedica reports Q4 results
Zomedica Pharmaceuticals Corp (ZOM)
Get Zomedica News Delivered to You Automatically

Sign up to receive the latest news and ratings for ZOM and its competitors with MarketBeat's FREE daily newsletter.

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

>> Register for the Workshop Now

ZOM Media Mentions By Week

ZOM Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ZOM
News Sentiment

-0.04

0.60

Average
Medical
News Sentiment

ZOM News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ZOM Articles
This Week

2

1

ZOM Articles
Average Week

Get Zomedica News Delivered to You Automatically

Sign up to receive the latest news and ratings for ZOM and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NYSEAMERICAN:ZOM) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners